ABILITY PHARMA

Clinical stage autophagy anti-cancer drug

Sector

Drug discovery

Stage

Phase I/II

Country

SPAIN

Clinical trials approved by US FDA, Spain Medicines Agency and French Medicines Agency

Patent granted already in the main markets: Europe, USA, Japan and Russia

Licensed for development and commercialization to SciClone Pharmaceuticals for Greater China, Taiwan and Vietnam

Potential sales in 2026: 2261M € (high scenario)

This information is confidential, do not share or copy.

Under evaluation till: 12 March 2018.

Click here and see what the BioExperts think of this company

See evaluation
Contact the entrepreneur

KEEP REVIEWING

©2019 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar